UPDATE: Tempest Therapeutics (TPST) PT Lowered to $35 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to UPDATE: Tempest Therapeutics (TPST) PT Lowered to $35 at H.C. Wainwright
May 13, 2022 8:00 AM EDT
Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCOPresented positive preclinical data for TPST-1495 at AACRPresented positive preclinical data with proprietary small molecule TREX1 inhibitors at AACR
SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today... More
May 13, 2022 8:00 AM EDT
Announced oral presentation of TPST-1120 Phase 1 monotherapy and combination therapy data at ASCOPresented positive preclinical data for TPST-1495 at AACRPresented positive preclinical data with proprietary small molecule TREX1 inhibitors at AACR
SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated... More
